Search
Haemonetics Corp
HAEAdd to Watchlist
107.350USD
-1.170-1.08%
Market hours 09/23, 15:31（ET）
4.88BMarket Cap
52.05P/E TTM
About Haemonetics Corp Company
Haemonetics Corporation is a global healthcare company. The Company is engaged in providing a suite of medical products and solutions for customers, to help them improve patient care and reduce the cost of healthcare. The Company’s technology addresses various medical markets, including blood and plasma component collection, the surgical suite, and hospital transfusion services. The Company’s Plasma segment includes plasma collection devices and disposables, donor management software and supporting software solutions sold to plasma customers. Its Blood Center segment manufactures and provides customers with its full line of apheresis solutions for automated blood collection. The Company’s Hospital segment consists of Interventional Technologies, which includes Vascular Closure, Sensor Guided Technologies and Esophageal Protection products, and Blood Management Technologies, which includes Hemostasis Management, Cell Salvage and Transfusion Management products.
Haemonetics Corp Profile
Ticker SymbolHAE
Company nameHaemonetics Corp
IPO dateOct 17, 1979
CEOSimon (Christopher A)
Number of employees3023
Security typeOrdinary Share
Fiscal year-endOct 17
Address125 Summer Street
CityBOSTON
Stock exchangeNASDAQ OMX NASDAQ Basic NYSE
CountryUnited States of America
Postal code02110
Phone17818487100
Websitehttps://www.haemonetics.com
Ticker SymbolHAE
IPO dateOct 17, 1979
CEOSimon (Christopher A)
Company Executives of Haemonetics Corp
Name
Name/Position
Position
Shareholding
Change
Ms. Laurie A. Miller
Ms. Laurie A. Miller
Chief Human Resources Officer, Senior Vice President
Chief Human Resources Officer, Senior Vice President
40.07K
-0.78%
Ms. Laurie A. Miller
Ms. Laurie A. Miller
Chief Human Resources Officer, Senior Vice President
Chief Human Resources Officer, Senior Vice President
40.07K
-0.78%
Ms. Michelle L. Basil, J.D.
Ms. Michelle L. Basil, J.D.
Executive Vice President, General Counsel
Executive Vice President, General Counsel
34.51K
+10.58%
Ms. Michelle L. Basil, J.D.
Ms. Michelle L. Basil, J.D.
Executive Vice President, General Counsel
Executive Vice President, General Counsel
34.51K
+10.58%
Mr. Robert E. Abernathy
Mr. Robert E. Abernathy
Independent Director
Independent Director
27.52K
+9.22%
Mr. Robert E. Abernathy
Mr. Robert E. Abernathy
Independent Director
Independent Director
27.52K
+9.22%
Dr. Mark W. Kroll, Ph.D.
Dr. Mark W. Kroll, Ph.D.
Independent Director
Independent Director
25.89K
+9.80%
Dr. Mark W. Kroll, Ph.D.
Dr. Mark W. Kroll, Ph.D.
Independent Director
Independent Director
25.89K
+9.80%
Mr. Charles J. Dockendorff, CPA
Mr. Charles J. Dockendorff, CPA
Independent Director
Independent Director
25.04K
--
Ms. Ellen M. Zane
Ms. Ellen M. Zane
Independent Chairman of the Board
Independent Chairman of the Board
21.91K
+11.58%
View more
Name
Name/Position
Position
Shareholding
Change
Ms. Laurie A. Miller
Ms. Laurie A. Miller
Chief Human Resources Officer, Senior Vice President
Chief Human Resources Officer, Senior Vice President
40.07K
-0.78%
Ms. Laurie A. Miller
Ms. Laurie A. Miller
Chief Human Resources Officer, Senior Vice President
Chief Human Resources Officer, Senior Vice President
40.07K
-0.78%
Ms. Michelle L. Basil, J.D.
Ms. Michelle L. Basil, J.D.
Executive Vice President, General Counsel
Executive Vice President, General Counsel
34.51K
+10.58%
Ms. Michelle L. Basil, J.D.
Ms. Michelle L. Basil, J.D.
Executive Vice President, General Counsel
Executive Vice President, General Counsel
34.51K
+10.58%
Mr. Robert E. Abernathy
Mr. Robert E. Abernathy
Independent Director
Independent Director
27.52K
+9.22%
Mr. Robert E. Abernathy
Mr. Robert E. Abernathy
Independent Director
Independent Director
27.52K
+9.22%
FAQs
Who are the top five shareholders of Haemonetics Corp?
The top five shareholders of Haemonetics Corp are: Ms. Laurie A. Miller
How many institutions hold shares of Haemonetics Corp (HAE)?
As of 2026Q1, 737 institutions hold shares of Haemonetics Corp, with a combined market value of approximately 58.91M, accounting for 126.77% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 664078.00.